Marathon Patent Group's Wholly-Owned Subsidiaries MedTech Development Deutschland GmbH and Orthophoenix LLC Enter Into Settlement and License Agreement

LOS ANGELES, CA -- (Marketwired) -- 06/09/15 -- Marathon Patent Group, Inc. (NASDAQ: MARA) ("Marathon"), a patent licensing company, announced today that its wholly-owned subsidiaries, MedTech Development Deutschland GmbH and Orthophoenix LLC, entered into settlement and license agreement. Due to a confidentiality agreement, the licensee may not be disclosed by name.

The consideration to be paid to MedTech Development Deutschland GmbH and Orthophoenix LLC and all other commercial terms of the license agreement are confidential.

The licensed patents include the German parts of European patent EP 1 938 765 B1 and EP 1 104 260 B2, both of which have been asserted in Germany and relate to medical devices involved in kyphoplasty surgery.

The Orthophoenix portfolio consists of patents, which relate to the treatment of bones including fractured and diseased bone elements. Claims coverage includes discharging a material into a bone cavity such that the bone assumes an expanded geometry. In addition to claims covering discharging a material into a bone structure the portfolio included additional patents and associated claims which address bone treatments in which an expandable structure is introduced into a collapsed bone and subsequently manipulated such that the structure forms an expanded geometry inside the bone. Exemplary patents in this portfolio include U.S. Patents 6,248,110, 6,280,456, 6,440,138, 7,044,954, and 6,863,672 with additional foreign patent grants providing International coverage.

About Marathon Patent Group

Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


Marathon Patent Group
Jason Assad

Source: Marathon Patent Group